<- Go Home

Alkermes plc

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Market Cap

$5.0B

Volume

1.8M

Cash and Equivalents

$399.8M

EBITDA

$419.0M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$1.3B

Profit Margin

84.42%

52 Week High

$36.45

52 Week Low

$22.90

Dividend

N/A

Price / Book Value

3.34

Price / Earnings

14.53

Price / Tangible Book Value

3.54

Enterprise Value

$4.2B

Enterprise Value / EBITDA

9.85

Operating Income

$391.1M

Return on Equity

25.71%

Return on Assets

11.62

Cash and Short Term Investments

$884.0M

Debt

$74.1M

Equity

$1.5B

Revenue

$1.5B

Unlevered FCF

$439.9M

Sector

Biotechnology

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches